Human mesenchymal stem cells genetically engineered to overexpress brain-derived neurotrophic factor improve outcomes in huntington's disease mouse models

Molecular Therapy

Volumn 24, Issue 5, 2016, Pages 965-977

  Pollock, Kari ^a   Dahlenburg, Heather ^a   Nelson, Haley ^a   Fink, Kyle D ^a   Cary, Whitney ^a   Hendrix, Kyle ^a   Annett, Geralyn ^a   Torrest, Audrey ^a   Deng, Peter ^a   Gutierrez, Joshua ^a   Nacey, Catherine ^a   Pepper, Karen ^a   Kalomoiris, Stefanos ^a   Anderson, Johnathon D ^a   McGee, Jeannine ^a   Gruenloh, William ^a   Fury, Brian ^a   Bauer, Gerhard ^a   Duffy, Alexandria ^b   Tempkin, Theresa ^b   Wheelock, Vicki ^b   Nolta, Jan A ^a   more..

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR;

ARTICLE; BRAIN SIZE; CELL DIFFERENTIATION; CELL POPULATION; CELL PROLIFERATION; CELL SURVIVAL; DRUG EFFICACY; GENE DELIVERY SYSTEM; GENE THERAPY; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; HUNTINGTON CHOREA; IMMUNE RESPONSE; LIFESPAN; MESENCHYMAL STEM CELL; MESENCHYMAL STEM CELL TRANSPLANTATION; NEUROPROTECTION; PHENOTYPE; PROTEIN EXPRESSION; PROTEIN FUNCTION; STRIATE CORTEX; TRANSCRIPTION REGULATION; TRANSGENE;

EID: 84961219463     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2016.12     Document Type: Article

References (97)

1. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington?s disease chromosomes The Huntington?s Disease Collaborative Research Group. Cell 72 971-983 (1993).
2. Huntington Study G (2006). Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial. Neurology 66: 366-372.
3. Killoran A and Biglan KM (2014). Current therapeutic options for Huntington?s disease: good clinical practice versus evidence-based approaches? Mov Disord 29: 1404-1413.
4. Scheuing L, Chiu CT, Liao HM, Linares GR and Chuang DM (2014). Preclinical and clinical investigations of mood stabilizers for Huntington?s disease: what have we learned? Int J Biol Sci 10: 1024-1038.
5. Canals JM, Pineda JR, Torres-Peraza JF, Bosch M, Martin-Ibanez R, Munoz MT, et al. (2004). Brain-derived neurotrophic factor regulates the onset and severity of motor dysfunction associated with enkephalinergic neuronal degeneration in Huntington?s disease. J Neurosci 24: 7727-7739.
6. Her LS and Goldstein LS (2008). Enhanced sensitivity of striatal neurons to axonal transport defects induced by mutant huntingtin. J Neurosci 28: 13662-13672.
7. Wu LL, Fan Y, Li S, Li XJ and Zhou XF (2010). Huntingtin-associated protein-1 interacts with pro-brain-derived neurotrophic factor and mediates its transport and release. J Biol Chem 285: 5614-5623.
8. Antoniades CA and Watts C (2013). Huntington?s disease and cell therapies: past, present, and future. Methods Mol Biol 1010: 19-32.
9. Torres-Peraza JF, Giralt A, Garcia-Martinez JM, Pedrosa E, Canals JM and Alberch J (2008). Disruption of striatal glutamatergic transmission induced by mutant huntingtin involves remodeling of both postsynaptic density and NMDA receptor signaling. Neurobiol Dis 29: 409-421.
10. Conforti P, Ramos C, Apostol BL, Simmons DA, Nguyen HP, Riess O, et al. (2008). Blood level of brain-derived neurotrophic factor mRNA is progressively reduced in rodent models of Huntington?s disease: restoration by the neuroprotective compound CEP-1347. Mol Cell Neurosci 39: 1-7.
11. Zuccato C, Belyaev N, Conforti P, Ooi L, Tartari M, Papadimou E, et al. (2007). Widespread disruption of repressor element-1 silencing transcription factor/neuronrestrictive silencer factor occupancy at its target genes in Huntington?s disease. J Neurosci 27: 6972-6983.
12. Ciammola A, Sassone J, Cannella M, Calza S, Poletti B, Frati L, et al. (2007). Low brain-derived neurotrophic factor (BDNF) levels in serum of Huntington?s disease patients. Am J Med Genet B Neuropsychiatr Genet 144B: 574-577.
13. Zuccato C, Liber D, Ramos C, Tarditi A, Rigamonti D, Tartari M, et al. (2005). Progressive loss of BDNF in a mouse model of Huntington?s disease and rescue by BDNF delivery. Pharmacol Res 52: 133-139.
14. Zuccato C, Ciammola A, Rigamonti D, Leavitt BR, Goffredo D, Conti L, et al. (2001). Loss of huntingtin-mediated BDNF gene transcription in Huntington?s disease. Science 293: 493-498.
15. Serrano Sanchez T, Alberti Amador E, Lorigados Pedre L, Blanco Lezcano L, Diaz Armesto I and Bergado JA (2014). BDNF in quinolinic acid lesioned rats after bone marrow cells transplant. Neurosci Lett 559: 147-151.
16. Samadi P, Boutet A, Rymar VV, Rawal K, Maheux J, Kvann JC, et al. (2013). Relationship between BDNF expression in major striatal afferents, striatum morphology and motor behavior in the R6/2 mouse model of Huntington?s disease. Genes Brain Behav 12: 108-124.
17. Martire A, Pepponi R, Domenici MR, Ferrante A, Chiodi V and Popoli P (2013). BDNF prevents NMDA-induced toxicity in models of Huntington?s disease: the effects are genotype specific and adenosine A2A receptor is involved. J Neurochem 125: 225-235.
18. Giampa C, Montagna E, Dato C, Melone MA, Bernardi G and Fusco FR (2013). Systemic delivery of recombinant brain derived neurotrophic factor (BDNF) in the R6/2 mouse model of Huntington?s disease. PLoS One 8: e64037.
19. Reiner A, Wang HB, Del Mar N, Sakata K, Yoo W and Deng YP (2012). BDNF may play a differential role in the protective effect of the mGluR2/3 agonist LY379268 on striatal projection neurons in R6/2 Huntington?s disease mice. Brain Res 1473: 161-172.
20. Benraiss A, Bruel-Jungerman E, Lu G, Economides AN, Davidson B and Goldman SA (2012). Sustained induction of neuronal addition to the adult rat neostriatum by AAV4-delivered noggin and BDNF. Gene Ther 19: 483-493.
21. Giralt A, Carreton O, Lao-Peregrin C, Martin ED and Alberch J (2011). Conditional BDNF release under pathological conditions improves Huntington?s disease pathology by delaying neuronal dysfunction. Mol Neurodegener 6: 71.
22. Arregui L, Benitez JA, Razgado LF, Vergara P and Segovia J (2011). Adenoviral astrocyte-specific expression of BDNF in the striata of mice transgenic for Huntington?s disease delays the onset of the motor phenotype. Cell Mol Neurobiol 31: 1229-1243.
23. Zajac MS, Pang TY, Wong N, Weinrich B, Leang LS, Craig JM, et al. (2010). Wheel running and environmental enrichment differentially modify exon-specific BDNF expression in the hippocampus of wild-type and pre-motor symptomatic male and female Huntington?s disease mice. Hippocampus 20: 621-636.
24. Xie Y, Hayden MR and Xu B (2010). BDNF overexpression in the forebrain rescues Huntington?s disease phenotypes in YAC128 mice. J Neurosci 30: 14708-14718.
25. Saylor AJ and McGinty JF (2010). An intrastriatal brain-derived neurotrophic factor infusion restores striatal gene expression in Bdnf heterozygous mice. Brain Struct Funct 215: 97-104.
26. Giralt A, Friedman HC, Caneda-Ferron B, Urban N, Moreno E, Rubio N, et al. (2010). BDNF regulation under GFAP promoter provides engineered astrocytes as a new approach for long-term protection in Huntington?s disease. Gene Ther 17: 1294-1308.
27. Dey ND, Bombard MC, Roland BP, Davidson S, Lu M, Rossignol J, et al. (2010). Genetically engineered mesenchymal stem cells reduce behavioral deficits in the YAC 128 mouse model of Huntington?s disease. Behav Brain Res 214: 193-200.
28. Wu CL, Hwang CS and Yang DI (2009). Protective effects of brain-derived neurotrophic factor against neurotoxicity of 3-nitropropionic acid in rat cortical neurons. Neurotoxicology 30: 718-726.
29. Simmons DA, Rex CS, Palmer L, Pandyarajan V, Fedulov V, Gall CM, et al. (2009). Up-regulating BDNF with an ampakine rescues synaptic plasticity and memory in Huntington?s disease knockin mice. Proc Natl Acad Sci USA 106: 4906-4911.
30. Giralt A, Rodrigo T, Martin ED, Gonzalez JR, Mila M, Cena V, et al. (2009). Brainderived neurotrophic factor modulates the severity of cognitive alterations induced by mutant huntingtin: involvement of phospholipaseCgamma activity and glutamate receptor expression. Neuroscience 158: 1234-1250.
31. Kells AP, Henry RA and Connor B (2008). AAV-BDNF mediated attenuation of quinolinic acid-induced neuropathology and motor function impairment. Gene Ther 15: 966-977.
32. Gharami K, Xie Y, An JJ, Tonegawa S and Xu B (2008). Brain-derived neurotrophic factor over-expression in the forebrain ameliorates Huntington?s disease phenotypes in mice. J Neurochem 105: 369-379.
33. Lynch G, Kramar EA, Rex CS, Jia Y, Chappas D, Gall CM, et al. (2007). Brainderived neurotrophic factor restores synaptic plasticity in a knock-in mouse model of Huntington?s disease. J Neurosci 27: 4424-4434.
34. Perez-Navarro E, Canudas AM, Akerund P, Alberch J and Arenas E (2000). Brainderived neurotrophic factor, neurotrophin-3, and neurotrophin-4/5 prevent the death of striatal projection neurons in a rodent model of Huntington?s disease. J Neurochem 75: 2190-2199.
35. Martinez-Serrano A and Bjorklund A (1996). Protection of the neostriatum against excitotoxic damage by neurotrophin-producing, genetically modified neural stem cells. J Neurosci 16: 4604-4616.
36. Alberch J, Perez-Navarro E and Canals JM (2004). Neurotrophic factors in Huntington?s disease. Prog Brain Res 146: 195-229.
37. Fink KD, Deng P, Torrest A, Stewart H, Pollock K, Gruenloh W, et al. (2015). Developing stem cell therapies for Juvenile and adult onset Huntington?s disease. Regen Med 10: 623-646.
38. Heliotis M and Tsiridis E (2008). Suppression of bone morphogenetic protein inhibitors promotes osteogenic differentiation: therapeutic implications. Arthritis Res Ther 10: 115.
39. Wan DC, Pomerantz JH, Brunet LJ, Kim JB, Chou YF, Wu BM, et al. (2007). Noggin suppression enhances in vitro osteogenesis and accelerates in vivo bone formation. J Biol Chem 282: 26450-26459.
40. Levi B, Nelson ER, Hyun JS, Glotzbach JP, Li S, Nauta A, et al. (2012). Enhancement of human adipose-derived stromal cell angiogenesis through knockdown of a BMP-2 inhibitor. Plast Reconstr Surg 129: 53-66.
41. Chen C, Uludag H, Wang Z and Jiang H (2012). Noggin suppression decreases BMP-2-induced osteogenesis of human bone marrow-derived mesenchymal stem cells in vitro. J Cell Biochem 113: 3672-3680.
42. Olson SD, Pollock K, Kambal A, Cary W, Mitchell GM, Tempkin J, et al. (2012). Genetically engineered mesenchymal stem cells as a proposed therapeutic for Huntington?s disease. Mol Neurobiol 45: 87-98.
43. Meyerrose T, et al. Establishment and Transduction of Primary Human Stromal/ Mesenchymal Stem Cell Monolayers. Chapter 2. Kluwer Academic Publishers, 2006.
44. Meyerrose T, Olson S, Pontow S, Kalomoiris S, Jung Y, Annett G, et al. (2010). Mesenchymal stem cells for the sustained in vivo delivery of bioactive factors. Adv Drug Deliv Rev 62: 1167-1174.
45. Murphy MB, Moncivais K and Caplan AI (2013). Mesenchymal stem cells: environmentally responsive therapeutics for regenerative medicine. Exp Mol Med 45: e54.
46. Mendonca MV, Larocca TF, de Freitas Souza BS, Villarreal CF, Silva LF, Matos AC, et al. (2014). Safety and neurological assessments after autologous transplantation of bone marrow mesenchymal stem cells in subjects with chronic spinal cord injury. Stem Cell Res Ther 5: 126.
47. Newell LF, Deans RJ and Maziarz RT (2014). Adult adherent stromal cells in the management of graft-versus-host disease. Expert Opin Biol Ther 14: 231-246.
48. Lunn JS, Sakowski SA and Feldman EL (2014). Concise review: Stem cell therapies for amyotrophic lateral sclerosis: recent advances and prospects for the future. Stem Cells 32: 1099-1109.
49. Lalu MM, Moher D, Marshall J, Fergusson D, Mei SH, Macleod M, et al.; Canadian Critical Care Translational Biology Group. (2014). Efficacy and safety of mesenchymal stromal cells in preclinical models of acute lung injury: a systematic review protocol. Syst Rev 3: 48.
50. Aleynik A, Gernavage KM, Mourad YSh Sherman LS, Liu K, Gubenko YA, et al. (2014). Stem cell delivery of therapies for brain disorders. Clin Transl Med 3: 24.
51. Munir H and McGettrick HM (2015). Mesenchymal stem cell therapy for autoimmune disease: risks and rewards. Stem Cells Dev 24: 2091-2100.
52. Uth K and Trifonov D (2014). Stem cell application for osteoarthritis in the knee joint: A minireview. World J Stem Cells 6: 629-636.
53. Ng TK, Fortino VR, Pelaez D and Cheung HS (2014). Progress of mesenchymal stem cell therapy for neural and retinal diseases. World J Stem Cells 6: 111-119.
54. Benraiss A and Goldman SA (2011). Cellular therapy and induced neuronal replacement for Huntington?s disease. Neurotherapeutics 8: 577-590.
55. Benraiss A, Toner MJ, Xu Q, Bruel-Jungerman E, Rogers EH, Wang F, et al. (2013). Sustained mobilization of endogenous neural progenitors delays disease progression in a transgenic model of Huntington?s disease. Cell Stem Cell 12: 787-799.
56. Rossignol J, Fink K, Davis K, Clerc S, Crane A, Matchynski J, et al. (2014). Transplants of adult mesenchymal and neural stem cells provide neuroprotection and behavioral sparing in a transgenic rat model of Huntington?s disease. Stem Cells 32: 500-509.
57. Rossignol J, Boyer C, Leveque X, Fink KD, Thinard R, Blanchard F, et al. (2011). Mesenchymal stem cell transplantation and DMEM administration in a 3NP rat model of Huntington?s disease: morphological and behavioral outcomes. Behav Brain Res 217: 369-378.
58. Lescaudron L, Unni D and Dunbar GL (2003). Autologous adult bone marrow stem cell transplantation in an animal model of huntington?s disease: behavioral and morphological outcomes. Int J Neurosci 113: 945-956.
59. Edalatmanesh MA, Matin MM, Neshati Z, Bahrami AR and Kheirabadi M (2010). Systemic transplantation of mesenchymal stem cells can reduce cognitive and motor deficits in rats with unilateral lesions of the neostriatum. Neurol Res 32: 166-172.
60. Snyder BR, Chiu AM, Prockop DJ and Chan AW (2010). Human multipotent stromal cells (MSCs) increase neurogenesis and decrease atrophy of the striatum in a transgenic mouse model for Huntington?s disease. PLoS One 5: e9347.
61. Dull T, Zufferey R, Kelly M, Mandel RJ, Nguyen M, Trono D, et al. (1998). A third-generation lentivirus vector with a conditional packaging system. J Virol 72: 8463-8471.
62. Challita PM, Skelton D, el-Khoueiry A, Yu XJ, Weinberg K and Kohn DB (1995). Multiple modifications in cis elements of the long terminal repeat of retroviral vectors lead to increased expression and decreased DNA methylation in embryonic carcinoma cells. J Virol 69: 748-755.
63. Candotti F, Shaw KL, Muul L, Carbonaro D, Sokolic R, Choi C, et al. (2012). Gene therapy for adenosine deaminase-deficient severe combined immune deficiency: clinical comparison of retroviral vectors and treatment plans. Blood 120: 3635-3646.
64. Folstein SE (1991). The psychopathology of Huntington?s disease. Res Publ Assoc Res Nerv Ment Dis 69: 181-191.
65. Anderson KE and Marder KS (2001). An overview of psychiatric symptoms in Huntington?s disease. Curr Psychiatry Rep 3: 379-388.
66. Craufurd D, Thompson JC and Snowden JS (2001). Behavioral changes in Huntington Disease. Neuropsychiatry Neuropsychol Behav Neurol 14: 219-226.
67. Crigler L, Robey RC, Asawachaicharn A, Gaupp D and Phinney DG (2006). Human mesenchymal stem cell subpopulations express a variety of neuro-regulatory molecules and promote neuronal cell survival and neuritogenesis. Exp Neurol 198: 54-64.
68. Kassis I, Grigoriadis N, Gowda-Kurkalli B, Mizrachi-Kol R, Ben-Hur T, Slavin S, et al. (2008). Neuroprotection and immunomodulation with mesenchymal stem cells in chronic experimental autoimmune encephalomyelitis. Arch Neurol 65: 753-761.
69. Berry SE (2015). Concise review: mesoangioblast and mesenchymal stem cell therapy for muscular dystrophy: progress, challenges, and future directions. Stem Cells Transl Med 4: 91-98.
70. Moll G, Alm JJ, Davies LC, von Bahr L, Heldring N, Stenbeck-Funke L, et al. (2014). Do cryopreserved mesenchymal stromal cells display impaired immunomodulatory and therapeutic properties? Stem Cells 32: 2430-2442.
71. Kingsman SM, Mitrophanous K and Olsen JC (2005). Potential oncogene activity of the woodchuck hepatitis post-transcriptional regulatory element (WPRE). Gene Ther 12: 3-4.
72. Rattray I, Smith EJ, Crum WR, Walker TA, Gale R, Bates GP, et al. (2013). Correlations of behavioral deficits with brain pathology assessed through longitudinal MRI and histopathology in the R6/1 mouse model of Huntington?s disease. PLoS One 8: e84726.
73. Southwell AL, Franciosi S, Villanueva EB, Xie Y, Winter LA, Veeraraghavan J, et al. (2015). Anti-semaphorin 4D immunotherapy ameliorates neuropathology and some cognitive impairment in the YAC128 mouse model of Huntington disease. Neurobiol Dis 76: 46-56.
74. Southwell AL, Warby SC, Carroll JB, Doty CN, Skotte NH, Zhang W, et al. (2013). A fully humanized transgenic mouse model of Huntington disease. Hum Mol Genet 22: 18-34.
75. Sokal EM, Lombard C and Mazza G (2015). Mesenchymal stem cell treatment for hemophilia: a review of current knowledge. J Thromb Haemost 13 Suppl 1: S161-S166.
76. Nordberg RC and Loboa EG (2015). Our fat future: translating adipose stem cell therapy. Stem Cells Transl Med 4: 974-979.
77. Luk F, de Witte SF, Bramer WM, Baan CC and Hoogduijn MJ (2015). Efficacy of immunotherapy with mesenchymal stem cells in man: a systematic review. Expert Rev Clin Immunol 11: 617-636.
78. Zhang ZX, Guan LX, Zhang K, Zhang Q and Dai LJ (2008). A combined procedure to deliver autologous mesenchymal stromal cells to patients with traumatic brain injury. Cytotherapy 10: 134-139.
79. Diez-Tejedor E, Gutierrez-Fernandez M, Martinez-Sanchez P, Rodriguez-Frutos B, Ruiz-Ares G, Lara ML, et al. (2014). Reparative therapy for acute ischemic stroke with allogeneic mesenchymal stem cells from adipose tissue: a safety assessment: a phase II randomized, double-blind, placebo-controlled, single-center, pilot clinical trial. J Stroke Cerebrovasc Dis 23: 2694-2700.
80. Haidet-Phillips AM and Maragakis NJ (2015). Neural and glial progenitor transplantation as a neuroprotective strategy for amyotrophic lateral sclerosis (ALS). Brain Res 1628(Pt B): 343-350.
81. Thomsen GM, Gowing G, Svendsen S and Svendsen CN (2014). The past, present and future of stem cell clinical trials for ALS. Exp Neurol 262 Pt B: 127-137.
82. Faravelli I, Riboldi G, Nizzardo M, Simone C, Zanetta C, Bresolin N, et al. (2014). Stem cell transplantation for amyotrophic lateral sclerosis: therapeutic potential and perspectives on clinical translation. Cell Mol Life Sci 71: 3257-3268.
83. Venkataramana NK, Kumar SK, Balaraju S, Radhakrishnan RC, Bansal A, Dixit A, et al. (2010). Open-labeled study of unilateral autologous bone-marrow-derived mesenchymal stem cell transplantation in Parkinson?s disease. Transl Res 155: 62-70.
84. Sharma RR, Pollock K, Hubel A and McKenna D (2014). Mesenchymal stem or stromal cells: a review of clinical applications and manufacturing practices. Transfusion 54: 1418-1437.
85. Bachoud-Levi AC (2009). Neural grafts in Huntington?s disease: viability after 10 years. Lancet Neurol 8: 979-981.
86. Bachoud-Levi AC, Deglon N, Nguyen JP, Bloch J, Bourdet C, Winkel L, et al. (2000). Neuroprotective gene therapy for Huntington?s disease using a polymer encapsulated BHK cell line engineered to secrete human CNTF. Hum Gene Ther 11: 1723-1729.
87. Bachoud-Levi AC, Gaura V, Brugieres P, Lefaucheur JP, Boisse MF, Maison P, et al. (2006). Effect of fetal neural transplants in patients with Huntington?s disease 6 years after surgery: a long-term follow-up study. Lancet Neurol 5: 303-309.
88. Bachoud-Levi AC, Remy P, Nguyen JP, Brugieres P, Lefaucheur JP, Bourdet C, et al. (2000). Motor and cognitive improvements in patients with Huntington?s disease after neural transplantation. Lancet 356: 1975-1979.
89. Gaura V, Bachoud-Levi AC, Ribeiro MJ, Nguyen JP, Frouin V, Baudic S, et al. (2004). Striatal neural grafting improves cortical metabolism in Huntington?s disease patients. Brain 127(Pt 1): 65-72.
90. Dunnett SB and Rosser AE (2011). Clinical translation of cell transplantation in the brain. Curr Opin Organ Transplant 16: 632-639.
91. Dunnett SB and Rosser AE (2011). Cell-based treatments for huntington?s disease. Int Rev Neurobiol 98: 483-508.
92. Zietlow R, Lane EL, Dunnett SB and Rosser AE (2008). Human stem cells for CNS repair. Cell Tissue Res 331: 301-322.
93. Dunnett SB and Rosser AE (2007). Stem cell transplantation for Huntington?s disease. Exp Neurol 203: 279-292.
94. Ogawa R, Mizuno H, Watanabe A, Migita M, Hyakusoku H and Shimada T (2004). Adipogenic differentiation by adipose-derived stem cells harvested from GFP transgenic mice-including relationship of sex differences. Biochem Biophys Res Commun 319: 511-517.
95. Olson SD, Kambal A, Pollock K, Mitchell GM, Stewart H, Kalomoiris S, et al. (2012). Examination of mesenchymal stem cell-mediated RNAi transfer to Huntington?s disease affected neuronal cells for reduction of huntingtin. Mol Cell Neurosci 49: 271-281.
96. Beegle J, Lakatos K, Kalomoiris S, Stewart H, Isseroff RR, Nolta JA, et al. (2015). Hypoxic preconditioning of mesenchymal stromal cells induces metabolic changes, enhances survival, and promotes cell retention in vivo. Stem Cells 33: 1818-1828.
97. Rosova I, Dao M, Capoccia B, Link D and Nolta JA (2008). Hypoxic preconditioning results in increased motility and improved therapeutic potential of human mesenchymal stem cells. Stem Cells 26: 2173-2182.